Merck & Co., Inc. (MRK) Stock

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Merck & Co., Inc. is led by CEO Robert Davis, employs 73,000 people, headquartered in Rahway, US, publicly traded since 1978.

Merck & Co., Inc. (MRK) stock trades at $128.57 with a market capitalization of $317.54B. The stock is valued at a price-to-earnings (P/E) ratio of 31.37, price-to-book of 5.24, price-to-sales of 4.34. Over the past 52 weeks the stock has ranged between $76.66 and $132.36, and currently trades 2.9% below its 52-week high. It pays a dividend yielding 2.92%.

On profitability, Merck & Co., Inc. generates a return on equity (ROE) of 18.94%, above the typical market average, return on capital employed of 44.60%, an operating margin of 41.19%, a net profit margin of 13.62%.

In its most recent fiscal year, Merck & Co., Inc. reported annual revenue of $64.9B, net profit of $18.3B, revenue has compounded at 9.4% a year over the last five years, profit at 20.9% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 1.07, a current ratio of 1.54, total assets of $136.9B, $14.6B in cash and equivalents.

MRK has an average daily trading volume of 10,140,000 shares, a beta of 0.22 (less volatile than the overall market).

Official website: www.merck.com